| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B Dubois, I McKeith, J M Orgogozo, O Collins, D Meulie. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. International journal of geriatric psychiatry. vol 14. issue 11. 2000-01-20. PMID:10556869. |
metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of alzheimer's disease (ad). |
2000-01-20 |
2023-08-12 |
Not clear |
| B M McGleenon, K B Dynan, A P Passmor. Acetylcholinesterase inhibitors in Alzheimer's disease. British journal of clinical pharmacology. vol 48. issue 4. 1999-12-16. PMID:10583015. |
acetylcholinesterase inhibitors in alzheimer's disease. |
1999-12-16 |
2023-08-12 |
Not clear |
| C Albrecht, H G Bloss, R Jackisch, T J Feuerstei. Evaluation of autoreceptor-mediated control of [(3)H]acetylcholine release in rat and human neocortex. Experimental brain research. vol 128. issue 3. 1999-11-24. PMID:10501810. |
the observation that in human neocortical tissue presynaptic autoinhibition of [(3)h]ach release is operative at stimulation frequencies >/= 6 hz suggests that selective blockade of autoinhibition may also increase ach release in the cortex of alzheimer's disease patients, without additional blockade of the enzyme acetylcholinesterase. |
1999-11-24 |
2023-08-12 |
human |
| F M Jacobsen, L Comas-Día. Donepezil for psychotropic-induced memory loss. The Journal of clinical psychiatry. vol 60. issue 10. 1999-11-10. PMID:10549687. |
donepezil is an acetylcholinesterase inhibitor marketed for treatment of memory loss and behavioral deterioration associated with the acetylcholine deficit of alzheimer's disease. |
1999-11-10 |
2023-08-12 |
Not clear |
| T Kosasa, Y Kuriya, K Matsui, Y Yamanish. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. European journal of pharmacology. vol 380. issue 2-3. 1999-11-01. PMID:10513568. |
the effects of oral administration of the centrally acting acetylcholinesterase (ache) inhibitors, donepezil hydrochloride (donepezil: e2020: (+/-)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-indan-1-one monohydrochloride), tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride) and ena-713 (rivastigmine: (s)-n-ethyl-3-[(1-dimethyl-amino)ethyl]-n-methyl-phenylcarbamate hydrogentartrate), which have been developed for the treatment of alzheimer's disease, on the extracellular acetylcholine concentration in the hippocampus of rats were evaluated by using a microdialysis technique without adding cholinesterase inhibitor to the perfusion solution. |
1999-11-01 |
2023-08-12 |
rat |
| S López-Pousa, C Lombardía Fernánde. [Treatment of Alzheimer's disease: acetylcholinesterase inhibitors]. Neurologia (Barcelona, Spain). vol 14. issue 4. 1999-10-26. PMID:10363493. |
[treatment of alzheimer's disease: acetylcholinesterase inhibitors]. |
1999-10-26 |
2023-08-12 |
Not clear |
| A Kur. [Effect pf anti-dementia drugs on the daily routine and attitude of dementia patients]. Zeitschrift fur Gerontologie und Geriatrie. vol 32. issue 3. 1999-10-14. PMID:10436496. |
the introduction of acetylcholinesterase inhibitors has greatly improved therapeutic opportunities for patients with dementia, in particular with alzheimer's disease. |
1999-10-14 |
2023-08-12 |
Not clear |
| P Camps, R El Achab, D M Görbig, J Morral, D Muñoz-Torrero, A Badia, J Eladi Baños, N M Vivas, X Barril, M Orozco, F J Luqu. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. Journal of medicinal chemistry. vol 42. issue 17. 1999-09-20. PMID:10464010. |
synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine a hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of alzheimer's disease. |
1999-09-20 |
2023-08-12 |
Not clear |
| R H Foster, G L Ploske. Donepezil. Pharmacoeconomic implications of therapy. PharmacoEconomics. vol 16. issue 1. 1999-08-31. PMID:10539126. |
donepezil is a specific acetylcholinesterase inhibitor that can improve symptoms in patients with mild-to-moderate alzheimer's disease; cognitive function is maintained above baseline levels for up to 1 year and normal decline of cognitive function is slowed. |
1999-08-31 |
2023-08-12 |
Not clear |
| W J Krall, J J Sramek, N R Cutle. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. The Annals of pharmacotherapy. vol 33. issue 4. 1999-07-20. PMID:10332536. |
to provide a review of acetylcholinesterase inhibitors (acheis) tested as therapeutic agents for alzheimer disease (ad). |
1999-07-20 |
2023-08-12 |
Not clear |
| G R Swanwick, B A Lawlo. Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease. International journal of geriatric psychiatry. vol 14. issue 4. 1999-07-07. PMID:10340182. |
the availability of acetylcholinesterase inhibitors for the treatment of alzheimer's disease raises a number of clinical and ethical questions. |
1999-07-07 |
2023-08-12 |
Not clear |
| C Y Li, H Wang, H Xue, P R Carlier, K M Hui, Y P Pang, Z W Li, Y F Ha. Bis(7)-tacrine, a novel dimeric AChE inhibitor, is a potent GABA(A) receptor antagonist. Neuroreport. vol 10. issue 4. 1999-06-29. PMID:10208550. |
heptylene-linked bis-(9-amino-1,2,3,4-tetrahydroacridine) (bis(7)-tacrine) is a potential palliative therapeutic agent for alzheimer's disease (ad), on the basis of its superior acetylcholinesterase (ache) inhibition and memory-enhancing potency relative to tacrine. |
1999-06-29 |
2023-08-12 |
rat |
| C S Ki, D L Na, J W Kim, H J Kim, D K Kim, B K Yoo. No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease. American journal of medical genetics. vol 88. issue 2. 1999-06-28. PMID:10206226. |
butyrylcholinesterase (bche) as well as acetylcholinesterase has been suggested to be associated with alzheimer's disease (ad). |
1999-06-28 |
2023-08-12 |
human |
| G Johnson, S W Moor. The adhesion function on acetylcholinesterase is located at the peripheral anionic site. Biochemical and biophysical research communications. vol 258. issue 3. 1999-06-24. PMID:10329459. |
there is accumulating evidence that acetylcholinesterase has secondary noncholinergic functions, related to adhesion, differentiation, and the deposition of beta-amyloid in alzheimer's disease. |
1999-06-24 |
2023-08-12 |
human |
| B R Ott, N J Owen. Complementary and alternative medicines for Alzheimer's disease. Journal of geriatric psychiatry and neurology. vol 11. issue 4. 1999-06-15. PMID:10230994. |
the recent successes of large, multicenter clinical trials of acetylcholinesterase inhibitors for symptomatic treatment of alzheimer's disease have spawned enthusiasm that this common and fatal neurologic disease is "treatable." |
1999-06-15 |
2023-08-12 |
Not clear |
| M A Raskind, P A Cyrus, B B Ruzicka, B I Gulansk. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. The Journal of clinical psychiatry. vol 60. issue 5. 1999-06-11. PMID:10362441. |
the objective of this study was to evaluate the efficacy and safety of metrifonate, a long-acting acetylcholinesterase inhibitor, in patients clinically diagnosed with probable alzheimer's disease of mild-to-moderate severity. |
1999-06-11 |
2023-08-12 |
Not clear |
| D E Moss, P Berlanga, M M Hagan, H Sandoval, C Ishid. Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. Alzheimer disease and associated disorders. vol 13. issue 1. 1999-05-25. PMID:10192638. |
the purpose of the present study was to evaluate methanesulfonyl fluoride (msf), a very long-acting cns-selective acetylcholinesterase (ache) inhibitor, as a palliative treatment for senile dementia of the alzheimer type (sdat). |
1999-05-25 |
2023-08-12 |
human |
| L P Sands, I Katz, L Schneide. Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors. Alzheimer disease and associated disorders. vol 13. issue 1. 1999-05-25. PMID:10192639. |
to evaluate an objective method for individually assessing alzheimer patients for cognitive benefits from acetylcholinesterase inhibitors, we conducted a secondary analysis of data from 234 subjects enrolled in a 30-week efficacy trial of tacrine hydrochloride. |
1999-05-25 |
2023-08-12 |
human |
| D E Kuhl, R A Koeppe, S Minoshima, S E Snyder, E P Ficaro, N L Foster, K A Frey, M R Kilbour. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. vol 52. issue 4. 1999-04-30. PMID:10078712. |
in vivo mapping of cerebral acetylcholinesterase activity in aging and alzheimer's disease. |
1999-04-30 |
2023-08-12 |
human |
| L Flicke. Acetylcholinesterase inhibitors for Alzheimer's disease. BMJ (Clinical research ed.). vol 318. issue 7184. 1999-04-22. PMID:10066180. |
acetylcholinesterase inhibitors for alzheimer's disease. |
1999-04-22 |
2023-08-12 |
Not clear |